IP Library Granted Patent US 10,006,052
Granted Patent B2
US 10,006,052 · App. 14/891,202 · Granted Jun 26, 2018

Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof

Inventors: Jordan Jarjour (Seattle, WA); Alexander Astrakhan (Seattle, WA)
Assignees: CELLECTIS; PRECISION GENOME ENGINEERING, INC.
C12N15/907A61K35/17A61K38/465C12N9/22C12Y301/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,006,052
App. No.
14/891,202
Granted
Jun 26, 2018
Kind
B2
Abstract

Disclosed herein are compositions for inactivating the human CCR5 gene comprising engineered LAGLIDADG homing endonucleases (LHEs) and their derivatives, particularly derived from members of the \-Onul subfamily of LHE. Polynucleotides encoding such endonucleases, vectors comprising said polynucleotides, cells comprising or having been treated with such endonucleases, and therapeutic compositions deriving therefrom are also provided.

Claims (20)

1. A chimeric endonuclease comprising:

an endonuclease domain having at least 90% identity with the amino acid sequence of SEQ ID NO:19 that cleaves a target nucleic acid sequence within the C-C chemokine receptor type 5 gene (CCR5), wherein the target nucleic acid sequence is SEQ ID NO:5; and

at least an additional protein domain selected from the group consisting of: nucleic acid binding domain, catalytic domain, terminal epitope tags and fluorescent proteins.

2. A chimeric endonuclease comprising:

an endonuclease domain having at least 70% identity with the amino acid sequence of SEQ ID NO:19 and having at least 95% identity with the DNA recognition interface of SEQ ID NO:19 that cleaves a target nucleic acid sequence within the C-C chemokine receptor type 5 gene (CCR5),

wherein the target nucleic acid sequence is SEQ ID NO:5 and,

wherein the endonuclease domain comprises at least 10 amino acid substitutions at positions selected from the group consisting of: amino acid position 19, 24, 26, 28, 30, 32, 34, 35, 36, 37, 38, 40, 42, 44, 46, 48, 68, 70, 72, 75, 76 77, 78, 80, 82, 168, 180, 182, 184, 186, 188, 189, 190, 191, 192, 193, 195, 197, 199, 201, 203, 223, 225, 227, 229, 231, 232, 234, 236, 238, and 240 in reference to SEQ ID NO:2,

and at least an additional protein domain selected from the group consisting of: nucleic acid binding domain, catalytic domain, terminal epitope tags and fluorescent proteins.

3. The chimeric endonuclease of claim 2 , comprising an endonuclease domain having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:19.

4. The chimeric endonuclease of claim 1 , wherein the chimeric endonuclease comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO17, SEQ ID NO:19 and SEQ ID NO:31.

5. The chimeric endonuclease of claim 2 , wherein the chimeric endonuclease comprises an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19 and SEQ ID NO.31.

6. The chimeric endonuclease of claim 1 , wherein the additional protein domain is a nucleic acid binding domain selected from the group consisting of TALE and Zinc Finger domain.

7. The chimeric endonuclease of claim 6 , wherein the chimeric endonuclease is the MegaTAL CCR5_S08 protein sequence selected from the group consisting of SEQ ID NO:25 and SEQ ID NO:33.

8. The chimeric endonuclease of claim 1 , wherein additional protein domain has catalytic activity selected from the group consisting of: nuclease activity, polymerase activity, kinase activity, phosphatase activity, methylase activity, topoisomerase activity, integrase activity, transposase activity, ligase activity, helicase activity, recombinase activity.

9. The chimeric endonuclease of claim 1 , wherein the catalytic domain is a 5′-3′ exonuclease, more preferably Trex2 and more preferably single chain Trex2.

10. The chimeric endonuclease of claim 1 , wherein the additional protein domain is fused to the endonuclease domain by a peptide linker.

11. The chimeric endonuclease of claim 1 , fused to a nucleic acid binding domain and a catalytic domain.

12. The chimeric endonuclease of claim 11 , wherein the additional protein domain is a nucleic acid binding domain selected from the group consisting of TALE and Zinc Finger domain.

13. The chimeric endonuclease of claim 11 , wherein the catalytic domain is a 5′-3′ exonuclease, more preferably Trex2 and more preferably single chain Trex2.

14. The chimeric endonuclease of claim 11 , wherein the chimeric endonuclease comprises the amino acid sequence set forth in SEQ ID NO:33.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2021
From: PRECISION GENOME ENGINEERING, INC.
To: 2SEVENTY BIO, INC.
Reel/Frame 057480/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2017
From: JARJOUR, JORDAN; ASTRAKHAN, ALEXANDER
To: CELLECTIS; PRECISION GENOME ENGINEERING, INC.
Reel/Frame 041098/0469 →
Priority Claims (1)
DK 2013 70302 · May 31, 2013 · national
Continuity (1)
Related Publication 20160102323A1 · Apr 14, 2016
Cited By (1)
US 12,584,149